CoChat
Sign Up
Cited by 19Growth Hormone and Insulin-like Growth FactorsDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Effects of growth hormone and pioglitazone in viscerally obese adults with impaired glucose tolerance: a factorial clinical trial

Open access
Attallah, Hamdee, Friedlander, Anne L, Nino-Murcia, Matilde, Hoffman, Andrew R·2007·PLoS Clinical Trials
DOI 10.1371/journal.pctr.0020021PMC PMC1865086
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: Recombinant human growth hormone (GH) and pioglitazone (PIO) in abdominally obese adults with impaired glucose tolerance were evaluated under the hypothesis that the combination attenuates GH-induced increases in glucose concentrations, reduces visceral adipose tissue (VAT), and improves insulin sensitivity over time. DESIGN: Randomized, double-blind, placebo-controlled, 2 x 2 factorial design. SETTING: Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States. PARTICIPANTS: 62 abdominally obese adults aged 40-75 with impaired glucose tolerance. INTERVENTIONS: GH (8 microg/kg/d, or placebo) and pioglitazone (30 mg/d, or placebo) for 40 wk. OUTCOME MEASURES: Baseline and after 40 wk of treatment, VAT content was quantified by CT scan, glucose tolerance was assessed using a 75-g oral glucose tolerance test, and insulin sensitivity was measured using steady-state plasma glucose levels obtained during insulin suppression test. RESULTS: BASELINE: body mass index (BMI), plasma glucose, and visceral fat content were similar. 40 wk: visceral fat area declined 23.9 +/- 7.4 cm(2) in GH group, mean difference from placebo: -28.1 cm(2) (95% CI -49.9 to -6.3 cm(2); p = 0.02). Insulin resistance declined 52 +/- 11.8 mg/dl with PIO, mean difference from placebo of -58.8 mg/dl (95% CI -99.7 to -18.0 mg/dl; p = 0.01). VAT and SSPG declined with GH and PIO combined, mean differences from placebo of -31.4 cm(2) (95% CI -56.5 cm(2) to -6.3 cm(2); p = 0.02) and -55.3 mg/dl (95% CI -103.9 to -6.7 mg/dl; p = 0.02), respectively. Fasting plasma glucose increased transiently in GH group. No significant changes in BMI were observed. CONCLUSIONS: Addition of PIO to GH attenuated the short-term diabetogenic effect of GH; the drug combination reduced VAT and insulin resistance over time. GH plus PIO may have added benefit on body composition and insulin sensitivity in the metabolic syndrome.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pctr.0020021

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Attallah, H., Friedlander, A. L., Nino-Murcia, M., & Hoffman, A. R.
Affiliations
  • Wayne State University (US)
  • VA Palo Alto Health Care System (US)
  • Stanford University (US)
Corresponding author
Hoffman, Andrew R
ORCID
Hoffman, Andrew R
Venue
PLoS Clinical Trials
Publisher
Public Library of Science (PLoS)
Published
2007-05-04
Volume
2
Issue
5
Pages
e21
ISSN
1555-5887 (ISSN-L)
DOI
10.1371/journal.pctr.0020021
PMC
PMC1865086
OpenAlex
W2126636860
Cited by
19
References
62
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2015: 1 · 2013: 3
FWCI
2.20
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS Clinical Trials (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
Funders
U.S. Department of Veterans Affairs
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
growth hormone, pioglitazone, visceral obesity, impaired glucose tolerance, visceral adipose tissue, insulin resistance, insulin sensitivity, glucose tolerance, combination therapy, veterans, body composition, fasting blood glucose, insulin suppression test, oral glucose tolerance test, antidiabetic drugs, antihypertensive drugs, antithrombotic agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review